How are energy investors positioned?
BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ: ACON, ACONW), a healthcare technology company, announced today that it has raised nearly $20 million in gross proceeds since January 1, 2025. This funding is set to fully support the CLARITY trial, a significant study aimed at validating the effectiveness of the company’s Nociscan platform in improving surgical outcomes for patients with chronic low back pain. According to InvestingPro data, the company maintains a healthy current ratio of 2.8, with cash reserves exceeding debt obligations, suggesting strong financial flexibility to support the trial’s execution.
The CLARITY trial, a prospective, randomized, multicenter clinical study, is led by Dr. Nicholas Theodore of Johns Hopkins. The trial will enroll 300 patients across various sites to assess Nociscan’s ability to match surgical interventions to the specific discs causing pain, based on peer-reviewed data. While the company’s stock has experienced significant volatility, trading near its 52-week low of $6.27, InvestingPro analysis suggests the stock is currently undervalued, with 15 additional ProTips available to subscribers.
Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary augmented intelligence algorithms to noninvasively identify painful discs in the lumbar spine by quantifying chemical biomarkers. This platform is reported to have achieved a 97% surgical success rate at a one-year follow-up when treating all Nociscan-identified pain-positive discs.
Chief Strategy Officer Ryan Bond commented on the significance of this milestone, expressing confidence in the trial’s potential to redefine treatment for chronic low back pain and secure broad payer coverage.
Aclarion’s innovative approach to addressing chronic low back pain, which affects approximately 266 million people worldwide, positions Nociscan as a first-of-its-kind, evidence-supported Software (ETR:SOWGn) as a Service (SaaS) platform in the healthcare technology market.
The information provided in this news article is based on a press release statement from Aclarion, Inc. It is important to note that forward-looking statements in the press release are subject to numerous uncertainties and risks that could affect the company’s future results and financial condition. With analysts forecasting a sales decline and the company trading at a price-to-book ratio of just 0.08, investors seeking deeper insights can access comprehensive financial analysis and real-time metrics through InvestingPro’s advanced analytics platform.
In other recent news, Aclarion, Inc., a healthcare technology company, has been making significant strides in its business strategy. The company’s NOCISCAN platform was presented at the Selby Spine Conference, where it was touted as a breakthrough in diagnosing the source of discogenic pain. The platform uses MR Spectroscopy and augmented intelligence to identify biomarkers for chronic low back pain.
In a bid to maintain compliance with Nasdaq’s listing standards, Aclarion executed a reverse stock split at a ratio of 1-for-335. This move resulted in the company’s gross proceeds reaching approximately $14.55 million and is expected to increase its stockholders’ equity to around $10.5 million. Following this development, Aclarion terminated its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, ending its ability to sell shares of its common stock through the "at the market" offering.
In addition, Aclarion extended its equity line agreement with White Lion Capital, LLC, introducing new pricing options for shares sold under the agreement and issuing White Lion 560,915 commitment shares. These recent developments are part of Aclarion’s broader business strategy, which aims to optimize its financial health and business operations. Despite facing profitability challenges, Aclarion maintains a strong liquidity position with a current ratio of 2.8, indicating its ability to meet short-term obligations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.